|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Corresponding in vivo differences in levels of TIMP-2, JAM-C, and TF were demonstrated in primary tumors grown in the chick embryo.
|
18658134 |
2008 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
MicroRNA-374 targets JAM-2 regulates the growth and metastasis of human pancreatic cancer cells.
|
31737197 |
2019 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Junctional adhesion molecule C (JAM-C) dimerization aids cancer cell migration and metastasis.
|
29378216 |
2018 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Junctional adhesion molecule 3 (Jam3) is a member of the junctional adhesion molecule family, which has been linked to epithelial and cancer cell proliferation.
|
30226554 |
2018 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Junctional adhesion molecule C (JAM-C) dimerization aids cancer cell migration and metastasis.
|
29378216 |
2018 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Junctional adhesion molecule 3 (Jam3) is a member of the junctional adhesion molecule family, which has been linked to epithelial and cancer cell proliferation.
|
30226554 |
2018 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Junctional adhesion molecule C (JAM-C) dimerization aids cancer cell migration and metastasis.
|
29378216 |
2018 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
These results suggest that <i>S</i>-palmitoylation of JAM-C can be potentially targeted to control cancer metastasis.
|
28196865 |
2017 |
|
Malignant Neoplasms
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Finally, we demonstrated that JAM-C controls Src family kinase (SFK) activation in LSC and that LIC with exacerbated SFK activation was uniquely found within the JAM-C-expressing LSC compartment.<i>Cancer Res; 77(23); 6627-40.©2017 AACR</i>.
|
28972073 |
2017 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
These results suggest that <i>S</i>-palmitoylation of JAM-C can be potentially targeted to control cancer metastasis.
|
28196865 |
2017 |
|
Primary malignant neoplasm
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Finally, we demonstrated that JAM-C controls Src family kinase (SFK) activation in LSC and that LIC with exacerbated SFK activation was uniquely found within the JAM-C-expressing LSC compartment.<i>Cancer Res; 77(23); 6627-40.©2017 AACR</i>.
|
28972073 |
2017 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
These results suggest that <i>S</i>-palmitoylation of JAM-C can be potentially targeted to control cancer metastasis.
|
28196865 |
2017 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
We found that JAM-C played an important role in different metastasis capacity of lymph node.
|
24584816 |
2014 |
|
Non-Small Cell Lung Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The present results indicate that miRNA-374b inhibits tumor growth and promotes apoptosis in NSCLC through the p38/ERK signaling pathway by targeting JAM-2.
|
30416798 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Leukemogenesis is almost completely abrogated upon Jam3 deletion during serial transplantations in an MLL-AF9-induced murine acute myeloid leukemia model.
|
29584620 |
2018 |
|
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
The key findings of the study demonstrated that miR-374b significantly inhibits cell proliferation, migration, and invasion through the blockade of the p38/ERK signaling pathway activation, as well as negatively binding to JAM-2, highlighting its potential as a therapeutic target for CC.
|
29575013 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.020 |
Biomarker
|
disease |
BEFREE |
JAM-C Identifies Src Family Kinase-Activated Leukemia-Initiating Cells and Predicts Poor Prognosis in Acute Myeloid Leukemia.
|
28972073 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
NSCLC tissue was analyzed for expression of junctional adhesion molecule-C (JAM-C) protein.
|
24584816 |
2014 |
|
Congenital cataract
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Delineation of the clinical, molecular and cellular aspects of novel JAM3 mutations underlying the autosomal recessive hemorrhagic destruction of the brain, subependymal calcification, and congenital cataracts.
|
23255084 |
2013 |
|
Jacobsen Distal 11q Deletion Syndrome
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Therefore, our findings do not support the traditional view of deletion size correlation in JBS or the causative role of FLI1, ETS1, NFRKB, and JAM3 deletion per se for the development of disease-related thrombocytopenia.
|
22887642 |
2012 |
|
Congenital cataract
|
0.020 |
Biomarker
|
disease |
BEFREE |
A homozygous mutation in the tight-junction protein JAM3 causes hemorrhagic destruction of the brain, subependymal calcification, and congenital cataracts.
|
21109224 |
2010 |
|
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Cooperative expression of junctional adhesion molecule-C and -B supports growth and invasion of glioma.
|
19795504 |
2010 |
|
Jacobsen Distal 11q Deletion Syndrome
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
These mice have normal cardiac structure and function, indicating that haplo-insufficiency of JAM-3 is unlikely to cause the congenital heart defects that occur in 11q- patients.
|
19533782 |
2009 |
|
Rheumatoid Arthritis
|
0.020 |
AlteredExpression
|
disease |
LHGDN |
Junctional adhesion molecule C mediates leukocyte adhesion to rheumatoid arthritis synovium.
|
18821692 |
2008 |
|
Rheumatoid Arthritis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In human tissue, JAM-C expression was increased in rheumatoid arthritis (RA) as compared to osteoarthritis synovial samples (12.7 +/- 1.3 arbitrary units in RA versus 3.3 +/- 1.1 in OA; p < 0.05).
|
17612407 |
2007 |